Thanks for the additional slides and clarifications.
I can’t recall if you have previously commented on REGN’s VEGF-Trap –i.e. whether it is likely to show better results than the kind of VEGF inhibition achieved by Avastin/Lucentis. If not, then perhaps now would be a good time to chime in :-)
I know that REGN’s partner, AVE, has plans to conduct human tests of VEGF-Trap in AMD. Moreover, VEGF-Trap has been given systemically in animal studies of AMD.
Market Data 
Markets 
AI
